|
Suntan
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure.
|
29739929 |
2018 |
|
Mental Depression
|
0.040 |
Biomarker
|
disease |
BEFREE |
Stroke patients older than 65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale.
|
29649015 |
2019 |
|
Mental Depression
|
0.040 |
Biomarker
|
disease |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Stroke patients older than 65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale.
|
29649015 |
2019 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Stroke patients older than 65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale.
|
29649015 |
2019 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Mental Depression
|
0.040 |
Biomarker
|
disease |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Mental Depression
|
0.040 |
Biomarker
|
disease |
BEFREE |
A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected.
|
23377640 |
2013 |
|
Depressive disorder
|
0.040 |
Biomarker
|
disease |
BEFREE |
A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected.
|
23377640 |
2013 |
|
Depressed mood
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
A meta-analysis was performed on data from three genome-wide pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the Munich Antidepressant Response Signature [MARS] project, and the Sequenced Treatment Alternatives to Relieve Depression [STAR*D] study), which included 2,256 individuals of Northern European descent with major depressive disorder, and antidepressant treatment outcomes were prospectively collected.
|
23377640 |
2013 |
|
Pseudotumor
|
0.030 |
Biomarker
|
disease |
BEFREE |
The prevalence of pseudotumors as determined with MARS-MRI was 59% in our high-risk group, 0% in the low-risk group and 43% in the control group.
|
29388037 |
2018 |
|
Pseudotumor
|
0.030 |
Biomarker
|
disease |
BEFREE |
Metal artifact reduction sequence magnetic resonance imaging (MARS MRI) was used for diagnosis of the pseudotumors, and serum metal ion levels and inflammatory marker levels were measured for all patients who underwent a revision due to pseudotumor.
|
29870445 |
2018 |
|
Liver Failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
A dynamic recirculation model for liver failure was used for upscaling and comparison against conventional MARS adsorbents as the gold standard in an albumin dialysis setting.
|
29266788 |
2018 |
|
Pseudotumor
|
0.030 |
Biomarker
|
disease |
BEFREE |
A total of 148 patients with dual taper modular THA were investigated: (1) 90 patients with pseudotumors detected with metal artifact reduction sequence-magnetic resonance imaging (MARS-MRI) and (2) 58 patients without pseudotumors on MARS-MRI.
|
27776907 |
2017 |
|
Liver Failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
MARS was used to support patients with severe liver trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liver failure (DT) in a level 1 trauma center and large transplant center.
|
28692474 |
2017 |
|
Liver Failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In paediatric liver failure, data on extracorporeal systems is scarce, comprising few reports on albumin dialysis (namely, Molecular Adsorbent Recirculating System; MARS) and plasma exchange.
|
28248208 |
2017 |
|
Major Depressive Disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809).
|
31383853 |
2019 |
|
Charcot-Marie-Tooth Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings underscore the phenotypic variability associated with ARS mutations, and suggest genetic or environmental modifying factors in the onset of monoallelic MARS-associated CMT2.
|
29655802 |
2018 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eligible PWE (n=760) completed the religiosity scale (Duke University Religion Index; DUREL) at baseline; the religious coping scale (Brief Religious Coping Scale; Brief RCOPE) one month later; the medication adherence scale (Medication Adherence Report Scale; MARS-5) two months later; and the QoL scale (Quality of Life in Epilepsy; QOLIE-31) twelve months later.
|
29175219 |
2018 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Instruments used at baseline and during a six-month follow-up period were the following: disease-specific self-efficacy (Epilepsy Self-Efficacy Scale [ESES], General Self-Efficacy Scale [GSES]); adherence (Medication Adherence Scale [MARS] and Medication Event Monitoring System [MEMS]); seizure severity (National Hospital Seizure Severity Scale [NHS3]); emotional well-being (Hospital Anxiety and Depression Scale [HADS]); quality of life (Quality of Life in Epilepsy [QOLIE-31P]); proactive coping (Utrecht Proactive Coping Competence [UPCC]); and side-effects of antiepileptic drugs [SIDAED].
|
29449140 |
2018 |
|
Pulmonary Alveolar Proteinosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In addition, pulmonary alveolar proteinosis is associated with mutations in CSF2RA, CSF2RB, and MARS, and specific auto-inflammatory forms of chILD implicate STING and COPA disorders.
|
29517585 |
2018 |
|
Pulmonary Alveolar Proteinosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In this work, we analyzed the effect of the PAP-related mutations in MARS on the thermal stability and on the catalytic parameters of the MetRS mutants, relative to wild-type.
|
29775242 |
2018 |